Physician profile

Jorge Galan

Gastroenterology (Internal Medicine) · Columbia, SC

NPI 1598746612

$13,486.71

in general payments reported to CMS, 2019-2025

44 companies · $1,618 in 2025

The $1,618 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,650.07
Education$22.59

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $4,211.84 2019-2025
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $2,051.57 2019-2025 Xifaxan, Trulance
Janssen Biotech, INC. $1,069.69 2019-2025 Tremfya, Stelara, Simponi Aria
Pfizer INC. $629.43 2019-2025
Takeda Pharmaceuticals U.S.A., INC. $617.63 2019-2025 Entyvio
Celgene Corporation $585.01 2021-2024 Zeposia
Qol Medical, LLC $583.57 2021-2025 Sucraid, Sucraid
Gilead Sciences, INC. $552.23 2020-2023
Genzyme Corporation $353.99 2022-2025
Ironwood Pharmaceuticals, INC $240.57 2019-2023 Linzess
Nestle Healthcare Nutrition INC. $209.54 2020-2023
Regeneron Healthcare Solutions, INC. $207.85 2022-2025 Dupixent
Ferring Pharmaceuticals INC. $199.66 2019-2025 Rebyota
Intercept Pharmaceuticals, INC. $175.23 2019-2024
Fresenius Kabi USA, LLC $171.84 2023-2024 Idacio
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Daiichi Sankyo INC. $161.24 2020-2025 Injectafer
Ardelyx, INC. $151.83 2022-2025 Ibsrela
Braintree Laboratories, INC. $150.91 2019-2025 Sutab, Suflave
Boston Scientific Corporation $130.67 2019-2021
Merck Sharp & Dohme LLC $129.65 2019-2023 Dificid
E.R. Squibb & Sons, L.L.C. $121.83 2022
Madrigal Pharmaceuticals $114.42 2024-2025 Rezdiffra, Resmetirom
Amgen INC. $83.72 2022-2023 Avsola, Amjevita
Lilly USA, LLC $57.02 2023-2024 Omvoh
Aimmune Therapeutics, INC. $55.16 2024-2025 Zenpep, Vowst
Redhill Biopharma INC. $54.35 2020-2021
Echosens North America, INC. $53.83 2019
Ucb, INC. $41.52 2019-2020
Phathom Pharmaceuticals, INC. $37.29 2025 Voquezna
Ipsen Biopharmaceuticals, INC $34.81 2025 Iqirvo
Alfasigma USA, INC. $28.52 2020-2021
Mallinckrodt Hospital Products INC. $26.11 2025 Terlivaz
Medtronic, INC. $22.68 2025 Interstim
Celltrion USA INC. $22.59 2024 Zymfentra
Romark Laboratories, Lc $19.83 2020
Mylan Institutional INC. $18.92 2023
Fujifilm Healthcare Americas Corporation $18.59 2025
Ethicon US, LLC $16.75 2022
Pharmacosmos Therapeutics INC. $14.45 2021
Alnylam Pharmaceuticals INC. $13.49 2021
W. L. Gore & Associates, INC. $12.86 2021
Endo Pharmaceuticals INC. $12.25 2020
Astrazeneca Pharmaceuticals LP $10.93 2019
Tetraphase Pharmaceuticals, INC. $10.84 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jorge Galan

$13,486.71

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $1,618 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).

https://glasscript.com/doctor/208635/jorge-galan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.